Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIGHT 2: Intra-arterial Lidocaine for Chronic Migraine
NCT07361549Phase 2Recruiting
- Sponsor
- Daniel A. Tonetti
- Start
- Sep 2026
- Primary completion
- Dec 2030
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of lidocaine in chronic migraine (2 arms), sponsored by Daniel A. Tonetti. Primary endpoint: Headache Impact Test-6 at 1 month. Started Sep 2026; status: recruiting.
02
Drugs
lidocaine
03
Conditions
chronic migraine
Beyond the preview
Go deeper on NCT07361549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07361549.